Orexo: Putting CVS Caremark In The Past
Edison | May 09, 2016 09:27AM ET
Orexo AB (ST:ORX) has successfully navigated a challenging Q1,16 with the loss of CVS Health Corp (NYSE:CVS) exclusive status at restricted plans, emerging with positive operating cash flow due to working capital and a focus on cost control (total spend down 17% vs Q4). In the near term, management priorities are Zubsolv revenue growth, balanced with appropriate sales investment to target profitability. Investment will increase as Zubsolv’s market access and reimbursement position improves, and federal legislation is passed significantly expanding the available market. Global expansion with a potential new ex-US partner for Zubsolv represents further upside; a deal is targeted for Q216, with European filing planned in H216.
Zubsolv: Balanced investment to capture growth
Increased investment in promotional activities depends on opportunities to gain market share: market access improvements and legislative change nationally. Increasing the number of patients with unrestricted access to Zubsolv and further growing the profitable cash and commercial segments are a key focus. Federally, proposed changes to government policy would expand access to opioid dependence treatment through both current and new prescribers.
To read the entire report Please click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.